S&P 500 Futures
(0.00%) 5 308.00 points
Dow J Futures
(0.04%) 40 159 points
Nasdaq Futures
(-0.01%) 18 502 points
Oil
(1.52%) $82.59
Gas
(-0.41%) $1.711
Gold
(0.93%) $2 233.30
Silver
(-0.10%) $24.73
Platinum
(0.36%) $913.00
USD/EUR
(0.38%) $0.927
USD/NOK
(0.67%) $10.84
USD/GBP
(0.15%) $0.792
USD/RUB
(-0.02%) $92.43

Realtime updates for Taisho Pharmaceutical [TAIPY]

Exchange: OTC Sector: Healthcare Industry: Drug Manufacturersā€”Specialty & Generic
Last Updated27 Mar 2024 @ 15:57

1.24% $ 14.08

Live Chart Being Loaded With Signals

Commentary (27 Mar 2024 @ 15:57):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally...

Stats
Today's Volume 958.00
Average Volume 1 127.00
Market Cap 4.62B
EPS $13.29 ( 2023-06-30 )
Last Dividend $0.110 ( 2021-09-28 )
Next Dividend $0 ( N/A )
P/E 82.82
ATR14 $0 (0.00%)

Taisho Pharmaceutical Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Taisho Pharmaceutical Financials

Annual 2023
Revenue: $301.38B
Gross Profit: $177.85B (59.01 %)
EPS: $57.93
Q3 2023
Revenue: $83.58B
Gross Profit: $46.48B (55.61 %)
EPS: $35.05
Q2 2023
Revenue: $82.30B
Gross Profit: $46.92B (57.01 %)
EPS: $37.66
Q1 2023
Revenue: $80.80B
Gross Profit: $48.28B (59.75 %)
EPS: $13.31

Financial Reports:

No articles found.

Taisho Pharmaceutical Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Taisho Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 7.14 - good (71.41%) | Divividend Growth Potential Score: 3.86 - Decrease likely (22.84%)
Information
First Dividend $0.113 2021-03-29
Last Dividend $0.110 2021-09-28
Next Dividend $0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 2 --
Total Paid Out $0.223 --
Avg. Dividend % Per Year 0.00% --
Score 2.67 --
Div. Sustainability Score 7.14
Div.Growth Potential Score 3.86
Div. Directional Score 5.50 --
Next Divdend (Est)
(2024-06-21)
$0 Estimate 0.00 %
Dividend Stability
0.05 Very Bad
Dividend Score
2.67
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Warning: Undefined variable $stockPricesArray in /home/getagraph/public_html/stock.php on line 1111

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
SREDY Ex Dividend Junior 2023-04-14 Sporadic 0 0.00%
IBDRY Ex Dividend Knight 2023-07-07 Semi-Annually 0 0.00%
BMBN Ex Dividend Knight 2023-06-30 Semi-Annually 0 0.00%
OUKPY Ex Dividend Knight 2023-05-04 Semi-Annually 0 0.00%
ENGIY Ex Dividend Junior 2023-05-01 Annually 0 0.00%
THYCF Ex Dividend Junior 2023-09-28 Annually 0 0.00%
JUMSY Ex Dividend Knight 2023-08-23 Semi-Annually 0 0.00%
CHRYY Ex Dividend Junior 2023-09-08 Annually 0 0.00%
RBSPF Ex Dividend Knight 2023-08-10 Semi-Annually 0 0.00%
FNFI Ex Dividend Knight 2023-09-07 Quarterly 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.02631.5009.4710.00[0 - 0.5]
returnOnAssetsTTM0.008381.2009.7210.00[0 - 0.3]
returnOnEquityTTM0.01041.500-0.996-1.494[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM5.160.80010.008.00[1 - 3]
quickRatioTTM4.190.80010.008.00[0.8 - 2.5]
cashRatioTTM3.041.50010.0010.00[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM87.551.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM769.922.0010.0010.00[0 - 30]
freeCashFlowPerShareTTM769.922.0010.0010.00[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM0.5721.0003.803.80[0.2 - 0.8]
operatingProfitMarginTTM0.05901.000-0.819-0.819[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM0.3190.800-1.209-0.967[0.5 - 2]
Total Score7.14

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM20.741.0008.010[1 - 100]
returnOnEquityTTM0.01042.50-0.640-1.494[0.1 - 1.5]
freeCashFlowPerShareTTM769.922.0010.0010.00[0 - 30]
dividendYielPercentageTTM0.005071.5009.870[0 - 0.4]
operatingCashFlowPerShareTTM769.922.0010.0010.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-0.04001.500-3.600[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1971.0007.580[0.1 - 0.5]
Total Score3.86

Taisho Pharmaceutical

Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators